Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial

Blood

Volumn 93, Issue 12, 1999, Pages 4131-4143

  Burnett, Alan K ^a   Grimwade, David ^b   Solomon, Ellen ^b   Wheatley, Keith ^b   Goldstone, Anthony H ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033564337     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4131     Document Type: Article

References (40)

1. Rowley JD, Golomb HM Dougherty C: 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1:549, 1977
2. Grimwade D, Solomon E: Characterisation of the PML/RARα rearrangement associated with t(15:17) acute promyelocytic leukaemia. Curr Top Microbiol Immunol 220:81, 1997
3. Rees JKH, Gray R: Comparison of 1+5 DAT and 3+10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial. Semin Oncol 14:32, 1987
4. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F: Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112, 1990
5. Tallman M, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543, 1992
6. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Clinical results. Blood 76:1704, 1990
7. Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Zhoa L, Gu L-J, Wang Z-Y: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
8. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202, 1995
9. Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, Evans R, Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Nat Acad Sci USA 89:2694, 1992
10. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340:1437, 1992
11. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreef M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy for acute promyelocytic leukemia withtretinoin (all-trans-retinoic acid). N Engl J Med 324:1385, 1991
12. Fenaux P, LeDeley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D: Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82:3241, 1993
13. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
14. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn V, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014, 1997
15. Frankel SR, Eardley A, Lauwers C, Weiss M, Warrell RP: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292, 1992
16. Degos L, Dombret H, Chomienne C, Daniel M-T, Miclea JM, Chastang C, Castaigne S, Fenaux P: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995
17. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK. Randomised comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 89:2311, 1997
18. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
19. Iqbal S, Grimwade D, Chase A, Goldstone AH, Burnett AK, Goldman JM, Swirsky D: Identification of PML/RARα rearrangements in suspected acute promyelocytic leukaemia (APL) using In situ hybridisation on bone marrow (BM) smears: A comparison of cytogenetics with RT-PCR in MRC ATRA trial patients. Br J Haematol 101:56, 1998 (abstr, suppl 1)
20. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett AK, Solomon E: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the MRC ATRA trial. Br J Haematol 94:557,1996
21. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E: Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 10:61, 1996
22. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, Dube I, Winfield DA, Kingston J, Hagermeijer A: Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 82:529, 1992
23. Gallagher RE, Li YP, Rao, S, Paietta E, Andersen J, Etkind P, Bennett JM, Tollman MS, Wiernik PH: Characterisation of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540, 1995
24. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F: Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukaemia. EMBO J 11:1397, 1992
25. Grimwade D, Gorman P Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett AK, Freemont P, Sheer D, Solomon E: Characterisation of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876, 1997
26. Goldstone AH, Burnett AK, Milligan DW, Prentice AG, Wheatley K: Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC Study of 800 patients. Blood 90:583a, 1997 (abstr, suppl 1)
27. Culligan DJ, Stevenson D, Lin Chee Y, Grimwade D: Acute promyelocytic leukaemia with t(11;17)(q33;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol 100:328, 1998
28. Tobal K, Saunders MJ, Grey MR, Yin JAL: Persistence of RARα-PML fusion mRNA detected by reverse-transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 90:615, 1995
29. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrell RP: All-trans retinoic acid for acute promyelocytic leukemia. Ann Intern Med 120:278, 1994
30. Wiley JS, Firkin FC: Reduction of pulmonary toxicity by prednisolone prophylaxis during all-transretinoic acid treatment of acute promyelocytic leukemia. Leukemia 9:774, 1995
31. Burnett AK, Goldstone AH, Stevens R, Hann I, Rees JK, Wheatley K: Biological characteristics of disease determine the outcome of allogeneic or autologous BMT in AML CRI. Blood 86:616a, 1995 (abstr, suppl 1)
32. Burnett AK, Goldstone AH, Stevens RF, Hann IM, Rees JKH, Gray RG, Wheatley K: Randomised comparison of addition of autologous bone-marrow transplantation in first remission: Results of MRC AML 10 trial. Lancet 351:700, 1998
33. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Mandelli F, Lo Coco F: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood 90:1321, 1997
34. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH: Association of PML-RARa fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An Intergroup molecular study. Blood 90:1656, 1997
35. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahl R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD: Secondary cytogenetic changes in acute promyelocytic leukemia-Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B Study. J Clin Oncol 15:1786, 1997
36. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G. Scheinberg DA, Warrell RP: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML-RAR-a isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843, 1994
37. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S: Prognostic significance of the RT-PCR assay of PML/RARα transcripts in acute promyelocytic leukemia. Leukemia 9:1478, 1995
38. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F: Early detection of relapse by prospective RT-PCR analysis of the PML/RARα fusion gene in patients with acute promyelo-cytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784, 1998
39. Tobal K, Yin JAL: RT-PCR method with increased sensitivity shows persistence of PML-RARα fusion transcripts in patients in long-term remission of APL. Leukemia 12:1349, 1998
40. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 6:986, 1996